โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Etichetta canale medico: 16 negli ultimi 7 giorni ๐ŸŽ Canale alimentare: 193 negli ultimi 7 giorni ๐Ÿงธ Canale: prodotti: 48 negli ultimi 7 giorni ๐ŸŸข Monitoraggio: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Ultimo recupero: 24 minuti fa โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Etichetta canale medico: 16 negli ultimi 7 giorni ๐ŸŽ Canale alimentare: 193 negli ultimi 7 giorni ๐Ÿงธ Canale: prodotti: 48 negli ultimi 7 giorni ๐ŸŸข Monitoraggio: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Ultimo recupero: 24 minuti fa
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฎ๐Ÿ‡น
๐Ÿ’Š

Ayvakyt

avapritinib
Tumori stromali gastrointestinali
โœ… Autorizzato
โœ…
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.

A cosa serve

Unresectable or metastatic gastrointestinal stromal tumour (GIST) AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. Advanced systemic mastocytosis (AdvSM) AYVAKYT is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy. Indolent systemic mastocytosis (ISM) AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment (see section 5.1).

โš ๏ธ Sicurezza del paziente

No

โš ๏ธ Aggregiamo avvisi ufficiali. Non forniamo consulenze mediche. Per decisioni mediche o legali, consulta l'ente di riferimento e un professionista qualificato.